A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens

被引：0
|
作者：
Scambia, G.
Parma, G.
Del Conte, G.
Hess, D.
Gadducci, A.
Katsaros, D.
Sessa, C.
Trudel, G. C.
Coceani, N.
Colombo, N.
机构：
[1] Univ Cattolica Sacro Cuore, Campobasso, Italy
[2] Ist Europeo Oncol, Milan, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Kantonsspital St Gallen, St Gallen, Switzerland
[5] Univ Pisa, Pisa, Italy
[6] Univ Turin, Turin, Italy
[7] Osped San Giovanni Bellinzona, Bellinzona, Switzerland
[8] Johnson & Johnson, Beerse, Belgium
[9] Sendo, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens
    Parma, Gabriella
    Mancari, Rosanna
    Del Conte, Gianluca
    Scambia, Giovanni
    Gadducci, Angiolo
    Hess, Dagmar
    Katsaros, Dionyssios
    Sessa, Cristiana
    Rinaldi, Andrea
    Bertoni, Francesco
    Vitali, Andrea
    Catapano, Carlo Vittorio
    Marsoni, Silvia
    van de Velde, Helgi
    Colombo, Nicoletta
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (05) : 792 - 800
  • [2] Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
    Verhaar-Langereis, M
    Karakus, A
    Van Eijkeren, M
    Voest, E
    Witteveen, E
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 65 - 70
  • [3] A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia
    Tomlinson, Benjamin K.
    Tuscano, Joseph M.
    Abedi, Mehrdad
    Welborn, Jeanna
    Arora, Mili
    O'Donnell, Robert T.
    Wun, Ted
    Jonas, Brian A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (11) : E291 - E294
  • [4] Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
    Vergote, Ignace
    Finkler, Neil J.
    Hall, James B.
    Melnyk, Ostap
    Edwards, Robert P.
    Jones, Marsha
    Keck, James G.
    Meng, Lisa
    Brown, Gail L.
    Rankin, Elaine M.
    Burke, James J.
    Boccia, Ralph V.
    Runowicz, Carolyn D.
    Rose, Peter G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (05) : 772 - 780
  • [5] Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in mesothelioma
    Skubitz, KM
    CANCER INVESTIGATION, 2002, 20 (5-6) : 693 - 699
  • [6] Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in sarcoma
    Skubitz, KM
    CANCER INVESTIGATION, 2003, 21 (02) : 167 - 176
  • [7] Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in renal cell cancer
    Skubitz, KM
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 101 - 104
  • [8] Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer
    Keith M. Skubitz
    Investigational New Drugs, 2002, 20 : 101 - 104
  • [9] Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients
    Bourgeois, Hugues
    Joly, Florence
    Pujade-Lauraine, Eric
    Cure, Herve
    Guastalla, Jean Paul
    Ferru, Aurelie
    Chabrun, Virginie
    Chieze, Stephanie
    Tourani, Jean-Marc
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 399 - 404
  • [10] Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
    Irvin, William J., Jr.
    Orlowski, Robert Z.
    Chiu, Wing-Keung
    Carey, Lisa A.
    Collichio, Frances A.
    Bernard, Philip S.
    Stijleman, Inge J.
    Perou, Charles
    Ivanova, Anastasia
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2010, 10 (06) : 465 - 470
12345